MX2015004258A - Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes. - Google Patents

Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes.

Info

Publication number
MX2015004258A
MX2015004258A MX2015004258A MX2015004258A MX2015004258A MX 2015004258 A MX2015004258 A MX 2015004258A MX 2015004258 A MX2015004258 A MX 2015004258A MX 2015004258 A MX2015004258 A MX 2015004258A MX 2015004258 A MX2015004258 A MX 2015004258A
Authority
MX
Mexico
Prior art keywords
cell
binding agent
ion exchange
cytotoxic agent
exchange membrane
Prior art date
Application number
MX2015004258A
Other languages
English (en)
Inventor
Xinfang Li
Wenjie Cheng
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2015004258A publication Critical patent/MX2015004258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

La invención proporciona procesos para preparar conjugados purificados de agente de unión celular y agente citotóxico que comprenden someter una mezcla que comprende un conjugado de agentes de unión celular y agentes citotóxicos y una o más impurezas a una membrana de cromatografía de intercambio iónico para retirar al menos una parte de las impurezas de la mescla, lo cual proporciona de esta manera un conjugado de agentes de unión celular y agentes citotóxicos purificado.
MX2015004258A 2012-10-04 2013-10-04 Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes. MX2015004258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
MX2015004258A true MX2015004258A (es) 2015-09-25

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004258A MX2015004258A (es) 2012-10-04 2013-10-04 Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes.

Country Status (13)

Country Link
US (1) US20150307596A1 (es)
EP (1) EP2903450A4 (es)
JP (1) JP2015535215A (es)
CN (1) CN105208876A (es)
AU (1) AU2013326897A1 (es)
CA (1) CA2886996A1 (es)
HK (1) HK1213148A1 (es)
IL (1) IL238111A0 (es)
IN (1) IN2015DN03203A (es)
MX (1) MX2015004258A (es)
RU (1) RU2015116883A (es)
SG (1) SG11201502430QA (es)
WO (1) WO2014055893A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609752A (en) 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
IN2015DN03202A (es) * 2012-10-04 2015-10-02 Immunogen Inc
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290513A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物
CN118290514A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201824A1 (en) * 2002-01-03 2003-07-24 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP5165387B2 (ja) * 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
NZ609752A (en) * 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
PT2437790T (pt) * 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
RS58367B1 (sr) * 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom

Also Published As

Publication number Publication date
IN2015DN03203A (es) 2015-10-02
SG11201502430QA (en) 2015-04-29
CN105208876A (zh) 2015-12-30
US20150307596A1 (en) 2015-10-29
HK1213148A1 (zh) 2016-06-30
EP2903450A4 (en) 2016-05-11
EP2903450A1 (en) 2015-08-12
RU2015116883A (ru) 2016-11-27
IL238111A0 (en) 2015-05-31
AU2013326897A1 (en) 2015-05-07
WO2014055893A1 (en) 2014-04-10
JP2015535215A (ja) 2015-12-10
CA2886996A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
MX2015004258A (es) Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes.
IN2015DN03202A (es)
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
MX2021005426A (es) Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
PH12015500243B1 (en) Glycoconjugation processes and compositions
NZ708727A (en) Conjugate compounds
PH12016501122A1 (en) Delayed release compositions of linaclotide
IN2015DN03327A (es)
PH12014501991B1 (en) Phenicol antibacterials
MY174883A (en) Treatment of brain cancer
IN2014MN02236A (es)
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
PH12014501327A1 (en) Processes for making magnolol analogs
GEP201706708B (en) Isoxazolidine derivatives
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
IN2012DE00826A (es)
IN2013CH04314A (es)
SG10201803880TA (en) Stable compositions of neuroactive peptides
IN2014DN07839A (es)
IN2013MU01226A (es)